BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Britannia Pharmaceuticals Limited Expands Nasal Powder Program With New Production Capability


10/19/2005 5:11:31 PM

Britannia Pharmaceuticals announced today that it has purchased a state-of-the art Omnidose system from Harro Hofliger GmbH to accelerate the development of its innovative nasal powder treatments. The Omnidose machine, which will be operated out of Cardinal Health Germany GmbH, will provide rapid, high-precision dosing of Britannia's apomorphine and dihydroergotamine (DHE) nasal powders for use in the company's late-stage development programs, through to commercial production. Apomorphine is a potent dopamine agonist used in the treatment of late-stage Parkinson's disease and erectile dysfunction. DHE is used to treat migraine headaches.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES